Global IVF Reach Igenomix is part of the Vitrolife Group, a global leader in reproductive health with products and services available in over 125 countries and a presence in more than 25 countries. Sales opportunities exist in expanding distribution, co-marketing, and bundled solutions across international markets and clinics.

End-to-End Solution The group focuses on the entire reproductive-health journey from testing to treatment outcomes, offering potential to upsell integrated systems that combine genetic testing with clinical devices, data analytics, and quality control solutions for IVF clinics.

Strategic Partnerships Past collaborations with Ferring and other entities indicate a readiness for joint R&D and co-development initiatives. There are opportunities to pursue new research collaborations, diagnostic targets, and therapeutic strategy development with pharma and biotech partners.

Quality and Scale With a clear emphasis on consistent quality, science-based products, and a sizable global footprint, there is potential to propose scalable, compliant solutions for large clinic networks seeking standardized equipment, services, and data management across regions.

Revenue Growth Potential Reported revenue in the range of hundreds of millions positions Igenomix for high-value deals in testing services, genetic assays, and related technologies. Target large fertility centers and hospital networks with comprehensive, multi-year procurement programs.